Cohance Lifesciences Limited has announced the appointment of Umang Vohra as Executive Chairman, effective May 1, 2026, and as Group CEO, effective May 20, 2026. Mr. Vohra, the former CEO of Cipla Limited, joins the organization to spearhead its next phase of transformation and growth. He succeeds Vivek Sharma, who will transition into an advisory role for the next 9 months to ensure a seamless leadership handover.
Strategic Leadership Transition
In a significant move to accelerate its growth, Cohance Lifesciences has named industry veteran Umang Vohra to lead the company. With over three decades of experience in the pharmaceutical sector, Mr. Vohra is tasked with driving the company’s evolution as a global leader in the technology-driven CDMO space. His appointment is the result of a deliberate, strategic decision by the Board to align the firm’s leadership with its ambitious long-term transformation goals.
Focus on Innovation and Growth
Cohance Lifesciences has established a robust market position through its expertise in complex chemistry, ADCs, oligonucleotides, and advanced process R&D. Supported by over 400 R&D scientists and integrated research centers, the company is deeply focused on science-led solutions for global pharmaceutical innovators. Mr. Vohra, who previously transformed two major Indian pharmaceutical enterprises, brings an owner-mindset intended to scale commercial operations and deepen customer partnerships.
Future Outlook
Outgoing Executive Chairman Vivek Sharma expressed pride in the foundation built over the past few years, which includes successfully integrating businesses and solidifying the company’s identity as a science-led CDMO. Mr. Vohra stated his excitement for the entrepreneurial opportunity ahead, emphasizing his intent to leverage the existing talent and technology to create sustained value for shareholders, employees, and customers.
Source: BSE
